Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors

Clinical Trial ID NCT01455259

PubWeight™ 6.37‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01455259

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
2 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
3 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012 1.19
4 Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015 1.06
5 Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer 2016 0.82
6 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
Next 100